Among GC cases having stage I & II disease only 38.0% were having reduced TP53 mRNA expression compared to 68.8% patients with stage III&IV disease and elevated TP53 mRNA expression (OR = 3.6; p = 0.005). This evidence concerns the gene TP53 and gastric cancer.